[96a5a0]: / output / allTrials / logical / NCT00002866_logical.json

Download this file

961 lines (961 with data), 58.6 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
{
"info": {
"nct_id": "NCT00002866",
"official_title": "A Phase I/II Study of Docetaxel and Epirubicin as First-Line Therapy for Metastatic Breast Cancer",
"inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 16 Years\nMust have maximum age of 120 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer Newly diagnosed or progressive metastatic disease with at least 1 metastatic target lesion No known clinical brain or leptomeningeal metastasis Phase I entry: Measurable and/or evaluable disease with an indicator lesion outside prior radiotherapy field Phase II entry: (closed as of 03/27/2000) Bidimensionally measurable disease with an indicator lesion outside prior radiotherapy field At least 1 x 1 cm on chest x-ray At least 2 x 2 cm on CT scan or ultrasound Skin lesion or node at least 1 x 1 cm No bone-only lesion Hormone receptor status: Not specified\n\nPATIENT CHARACTERISTICS: Age: 16 and over Sex: Female Menopausal status: Not specified Performance status: ECOG 0-2 Hematopoietic: Absolute granulocyte count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than the upper limit of normal (ULN) AST/ALT no greater than 1.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN (no greater than 5.0 times ULN if AST/ALT normal) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: Left ventricular ejection fraction at least 50% at rest by MUGA or echocardiogram No congestive heart failure No angina pectoris (even if controlled) No myocardial infarction within the past year No uncontrolled arrhythmia No uncontrolled hypertension Other: No active infection No grade 2 or greater symptomatic peripheral neuropathy No significant neurologic or psychiatric disorder, including dementia or seizures No peptic ulcer, unstable diabetes mellitus, or other contraindication to dexamethasone No prior malignancy except nonmelanomatous skin cancer or excised carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use effective contraception Geographically accessible\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent supportive colony-stimulating factors (e.g., filgrastim (G -CSF)) (Prophylactic treatment during the second step of phase I allowed) Chemotherapy: Phase I patients: At least 12 months since prior adjuvant chemotherapy Prior neoadjuvant chemotherapy allowed Prior cumulative dose of doxorubicin no greater than 300 mg/m2 Prior cumulative dose of epirubicin no greater than 500 mg/m2 If epirubicin dose level at least 90 mg/m2: Prior cumulative dose of doxorubicin no greater than 200 mg/m2 Prior cumulative dose of epirubicin no greater than 300 mg/m2 Phase II patients: (closed as of 03/27/2000) No prior neoadjuvant or adjuvant chemotherapy regimen other than cyclophosphamide, methotrexate, and fluorouracil, or doxorubicin and cyclophosphamide given for a maximum of 4 courses All patients: No prior chemotherapy for metastatic disease No prior taxanes Endocrine therapy: Prior hormonal therapy in the adjuvant and/or metastatic setting allowed if subsequent disease progression No more than 2 prior hormonal therapy regimens for metastatic disease No concurrent corticosteroids (except for premedication or hypersensitivity reaction) Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy (unless single fractions for palliation) Concurrent local palliative radiotherapy for control of bone pain or for other reasons with no curative intent allowed Concurrent whole-brain radiotherapy for brain metastasis allowed No concurrent radiotherapy to sole measurable lesion Surgery: Not specified Other: No other concurrent investigational drugs or anticancer therapy No concurrent preventive IV antibiotics"
},
"inclusion_lines": [
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "female"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "female"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 16 Years",
"criterions": [
{
"exact_snippets": "minimum age of 16 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 16,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 16 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 16,
"unit": "Years"
}
}
}
]
}
},
{
"identified_line": {
"line": "Must have maximum age of 120 Years",
"criterions": [
{
"exact_snippets": "maximum age of 120 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 120,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "maximum age of 120 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 120,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"identified_line": {
"line": "DISEASE CHARACTERISTICS: Histologically or cytologically confirmed breast cancer Newly diagnosed or progressive metastatic disease with at least 1 metastatic target lesion No known clinical brain or leptomeningeal metastasis Phase I entry: Measurable and/or evaluable disease with an indicator lesion outside prior radiotherapy field Phase II entry: (closed as of 03/27/2000) Bidimensionally measurable disease with an indicator lesion outside prior radiotherapy field At least 1 x 1 cm on chest x-ray At least 2 x 2 cm on CT scan or ultrasound Skin lesion or node at least 1 x 1 cm No bone-only lesion Hormone receptor status: Not specified",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
},
{
"exact_snippets": "Newly diagnosed or progressive metastatic disease",
"criterion": "metastatic disease",
"requirement": {
"requirement_type": "status",
"expected_value": [
"newly diagnosed",
"progressive"
]
}
},
{
"exact_snippets": "at least 1 metastatic target lesion",
"criterion": "metastatic target lesion",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
}
},
{
"exact_snippets": "No known clinical brain or leptomeningeal metastasis",
"criterion": "brain or leptomeningeal metastasis",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Phase I entry: Measurable and/or evaluable disease with an indicator lesion outside prior radiotherapy field",
"criterion": "indicator lesion outside prior radiotherapy field",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Phase II entry: (closed as of 03/27/2000) Bidimensionally measurable disease with an indicator lesion outside prior radiotherapy field",
"criterion": "bidimensionally measurable disease",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "At least 1 x 1 cm on chest x-ray",
"criterion": "lesion size on chest x-ray",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
},
{
"exact_snippets": "At least 2 x 2 cm on CT scan or ultrasound",
"criterion": "lesion size on CT scan or ultrasound",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "cm"
}
}
},
{
"exact_snippets": "Skin lesion or node at least 1 x 1 cm",
"criterion": "skin lesion or node size",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
},
{
"exact_snippets": "No bone-only lesion",
"criterion": "bone-only lesion",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Hormone receptor status: Not specified",
"criterion": "hormone receptor status",
"requirement": {
"requirement_type": "specification",
"expected_value": "Not specified"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Histologically or cytologically confirmed breast cancer",
"criterion": "breast cancer",
"requirement": {
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
},
{
"exact_snippets": "Newly diagnosed or progressive metastatic disease",
"criterion": "metastatic disease",
"requirement": {
"requirement_type": "status",
"expected_value": [
"newly diagnosed",
"progressive"
]
}
}
]
},
{
"exact_snippets": "at least 1 metastatic target lesion",
"criterion": "metastatic target lesion",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
}
}
]
},
{
"exact_snippets": "No known clinical brain or leptomeningeal metastasis",
"criterion": "brain or leptomeningeal metastasis",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
{
"exact_snippets": "Phase I entry: Measurable and/or evaluable disease with an indicator lesion outside prior radiotherapy field",
"criterion": "indicator lesion outside prior radiotherapy field",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"exact_snippets": "Phase II entry: (closed as of 03/27/2000) Bidimensionally measurable disease with an indicator lesion outside prior radiotherapy field",
"criterion": "bidimensionally measurable disease",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "At least 1 x 1 cm on chest x-ray",
"criterion": "lesion size on chest x-ray",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
},
{
"exact_snippets": "At least 2 x 2 cm on CT scan or ultrasound",
"criterion": "lesion size on CT scan or ultrasound",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "cm"
}
}
},
{
"exact_snippets": "Skin lesion or node at least 1 x 1 cm",
"criterion": "skin lesion or node size",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
}
]
}
]
},
{
"exact_snippets": "No bone-only lesion",
"criterion": "bone-only lesion",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
{
"exact_snippets": "Hormone receptor status: Not specified",
"criterion": "hormone receptor status",
"requirement": {
"requirement_type": "specification",
"expected_value": "Not specified"
}
}
]
}
]
},
{
"exact_snippets": "Phase II entry: (closed as of 03/27/2000) Bidimensionally measurable disease with an indicator lesion outside prior radiotherapy field",
"criterion": "bidimensionally measurable disease",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"or_criteria": [
{
"exact_snippets": "At least 1 x 1 cm on chest x-ray",
"criterion": "lesion size on chest x-ray",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
},
{
"exact_snippets": "At least 2 x 2 cm on CT scan or ultrasound",
"criterion": "lesion size on CT scan or ultrasound",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "cm"
}
}
},
{
"exact_snippets": "Skin lesion or node at least 1 x 1 cm",
"criterion": "skin lesion or node size",
"requirement": {
"requirement_type": "size",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
}
]
}
]
}
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"identified_line": {
"line": "PATIENT CHARACTERISTICS: Age: 16 and over Sex: Female Menopausal status: Not specified Performance status: ECOG 0-2 Hematopoietic: Absolute granulocyte count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than the upper limit of normal (ULN) AST/ALT no greater than 1.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN (no greater than 5.0 times ULN if AST/ALT normal) Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: Left ventricular ejection fraction at least 50% at rest by MUGA or echocardiogram No congestive heart failure No angina pectoris (even if controlled) No myocardial infarction within the past year No uncontrolled arrhythmia No uncontrolled hypertension Other: No active infection No grade 2 or greater symptomatic peripheral neuropathy No significant neurologic or psychiatric disorder, including dementia or seizures No peptic ulcer, unstable diabetes mellitus, or other contraindication to dexamethasone No prior malignancy except nonmelanomatous skin cancer or excised carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use effective contraception Geographically accessible",
"criterions": [
{
"exact_snippets": "Age: 16 and over",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 16,
"unit": "years"
}
}
},
{
"exact_snippets": "Sex: Female",
"criterion": "sex",
"requirement": {
"requirement_type": "value",
"expected_value": "female"
}
},
{
"exact_snippets": "Performance status: ECOG 0-2",
"criterion": "performance status",
"requirement": {
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "ECOG"
},
{
"operator": "<=",
"value": 2,
"unit": "ECOG"
}
]
}
}
},
{
"exact_snippets": "Absolute granulocyte count at least 2,000/mm3",
"criterion": "absolute granulocyte count",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 2000,
"unit": "mm3"
}
}
},
{
"exact_snippets": "Platelet count at least 100,000/mm3",
"criterion": "platelet count",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm3"
}
}
},
{
"exact_snippets": "Hemoglobin at least 10 g/dL",
"criterion": "hemoglobin",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 10,
"unit": "g/dL"
}
}
},
{
"exact_snippets": "Bilirubin no greater than the upper limit of normal (ULN)",
"criterion": "bilirubin",
"requirement": {
"requirement_type": "maximum",
"expected_value": "ULN"
}
},
{
"exact_snippets": "AST/ALT no greater than 1.5 times ULN",
"criterion": "AST/ALT",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "times ULN"
}
}
},
{
"exact_snippets": "Alkaline phosphatase no greater than 2.5 times ULN (no greater than 5.0 times ULN if AST/ALT normal)",
"criterion": "alkaline phosphatase",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "times ULN"
}
}
},
{
"exact_snippets": "Alkaline phosphatase no greater than 2.5 times ULN (no greater than 5.0 times ULN if AST/ALT normal)",
"criterion": "alkaline phosphatase",
"requirement": {
"requirement_type": "conditional maximum",
"expected_value": {
"operator": "<=",
"value": 5.0,
"unit": "times ULN"
}
}
},
{
"exact_snippets": "Creatinine no greater than 1.5 times ULN",
"criterion": "creatinine",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "times ULN"
}
}
},
{
"exact_snippets": "Left ventricular ejection fraction at least 50% at rest by MUGA or echocardiogram",
"criterion": "left ventricular ejection fraction",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
}
},
{
"exact_snippets": "No congestive heart failure",
"criterion": "congestive heart failure",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No angina pectoris (even if controlled)",
"criterion": "angina pectoris",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No myocardial infarction within the past year",
"criterion": "myocardial infarction",
"requirement": {
"requirement_type": "recency",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "year"
}
}
},
{
"exact_snippets": "No uncontrolled arrhythmia",
"criterion": "uncontrolled arrhythmia",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No uncontrolled hypertension",
"criterion": "uncontrolled hypertension",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No active infection",
"criterion": "active infection",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No grade 2 or greater symptomatic peripheral neuropathy",
"criterion": "symptomatic peripheral neuropathy",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "grade"
}
}
},
{
"exact_snippets": "No significant neurologic or psychiatric disorder, including dementia or seizures",
"criterion": "significant neurologic or psychiatric disorder",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No peptic ulcer, unstable diabetes mellitus, or other contraindication to dexamethasone",
"criterion": "peptic ulcer, unstable diabetes mellitus, or other contraindication to dexamethasone",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No prior malignancy except nonmelanomatous skin cancer or excised carcinoma in situ of the cervix",
"criterion": "prior malignancy",
"requirement": {
"requirement_type": "exceptions",
"expected_value": [
"nonmelanomatous skin cancer",
"excised carcinoma in situ of the cervix"
]
}
},
{
"exact_snippets": "Not pregnant or nursing",
"criterion": "pregnancy or nursing",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Fertile patients must use effective contraception",
"criterion": "contraception use",
"requirement": {
"requirement_type": "requirement",
"expected_value": "fertile patients"
}
},
{
"exact_snippets": "Geographically accessible",
"criterion": "geographical accessibility",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent supportive colony-stimulating factors (e.g., filgrastim (G -CSF)) (Prophylactic treatment during the second step of phase I allowed) Chemotherapy: Phase I patients: At least 12 months since prior adjuvant chemotherapy Prior neoadjuvant chemotherapy allowed Prior cumulative dose of doxorubicin no greater than 300 mg/m2 Prior cumulative dose of epirubicin no greater than 500 mg/m2 If epirubicin dose level at least 90 mg/m2: Prior cumulative dose of doxorubicin no greater than 200 mg/m2 Prior cumulative dose of epirubicin no greater than 300 mg/m2 Phase II patients: (closed as of 03/27/2000) No prior neoadjuvant or adjuvant chemotherapy regimen other than cyclophosphamide, methotrexate, and fluorouracil, or doxorubicin and cyclophosphamide given for a maximum of 4 courses All patients: No prior chemotherapy for metastatic disease No prior taxanes Endocrine therapy: Prior hormonal therapy in the adjuvant and/or metastatic setting allowed if subsequent disease progression No more than 2 prior hormonal therapy regimens for metastatic disease No concurrent corticosteroids (except for premedication or hypersensitivity reaction) Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy (unless single fractions for palliation) Concurrent local palliative radiotherapy for control of bone pain or for other reasons with no curative intent allowed Concurrent whole-brain radiotherapy for brain metastasis allowed No concurrent radiotherapy to sole measurable lesion Surgery: Not specified Other: No other concurrent investigational drugs or anticancer therapy No concurrent preventive IV antibiotics",
"criterions": [
{
"exact_snippets": "No concurrent supportive colony-stimulating factors (e.g., filgrastim (G -CSF))",
"criterion": "concurrent supportive colony-stimulating factors",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Phase I patients: At least 12 months since prior adjuvant chemotherapy",
"criterion": "time since prior adjuvant chemotherapy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "months"
}
}
},
{
"exact_snippets": "Prior cumulative dose of doxorubicin no greater than 300 mg/m2",
"criterion": "cumulative dose of doxorubicin",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 300,
"unit": "mg/m2"
}
}
},
{
"exact_snippets": "Prior cumulative dose of epirubicin no greater than 500 mg/m2",
"criterion": "cumulative dose of epirubicin",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 500,
"unit": "mg/m2"
}
}
},
{
"exact_snippets": "If epirubicin dose level at least 90 mg/m2: Prior cumulative dose of doxorubicin no greater than 200 mg/m2",
"criterion": "cumulative dose of doxorubicin with epirubicin dose level at least 90 mg/m2",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 200,
"unit": "mg/m2"
}
}
},
{
"exact_snippets": "If epirubicin dose level at least 90 mg/m2: Prior cumulative dose of epirubicin no greater than 300 mg/m2",
"criterion": "cumulative dose of epirubicin with epirubicin dose level at least 90 mg/m2",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "<=",
"value": 300,
"unit": "mg/m2"
}
}
},
{
"exact_snippets": "Phase II patients: (closed as of 03/27/2000) No prior neoadjuvant or adjuvant chemotherapy regimen other than cyclophosphamide, methotrexate, and fluorouracil, or doxorubicin and cyclophosphamide given for a maximum of 4 courses",
"criterion": "prior neoadjuvant or adjuvant chemotherapy regimen for Phase II patients",
"requirement": {
"requirement_type": "allowed regimens",
"expected_value": [
"cyclophosphamide, methotrexate, and fluorouracil",
"doxorubicin and cyclophosphamide"
]
}
},
{
"exact_snippets": "Phase II patients: (closed as of 03/27/2000) No prior neoadjuvant or adjuvant chemotherapy regimen other than cyclophosphamide, methotrexate, and fluorouracil, or doxorubicin and cyclophosphamide given for a maximum of 4 courses",
"criterion": "prior neoadjuvant or adjuvant chemotherapy regimen for Phase II patients",
"requirement": {
"requirement_type": "maximum courses",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "courses"
}
}
},
{
"exact_snippets": "All patients: No prior chemotherapy for metastatic disease",
"criterion": "prior chemotherapy for metastatic disease",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No prior taxanes",
"criterion": "prior taxanes",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Prior hormonal therapy in the adjuvant and/or metastatic setting allowed if subsequent disease progression",
"criterion": "prior hormonal therapy in the adjuvant and/or metastatic setting",
"requirement": {
"requirement_type": "condition",
"expected_value": "allowed if subsequent disease progression"
}
},
{
"exact_snippets": "No more than 2 prior hormonal therapy regimens for metastatic disease",
"criterion": "prior hormonal therapy regimens for metastatic disease",
"requirement": {
"requirement_type": "maximum regimens",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "regimens"
}
}
},
{
"exact_snippets": "No concurrent corticosteroids (except for premedication or hypersensitivity reaction)",
"criterion": "concurrent corticosteroids",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No concurrent corticosteroids (except for premedication or hypersensitivity reaction)",
"criterion": "concurrent corticosteroids",
"requirement": {
"requirement_type": "exceptions",
"expected_value": [
"premedication",
"hypersensitivity reaction"
]
}
},
{
"exact_snippets": "At least 4 weeks since prior radiotherapy (unless single fractions for palliation)",
"criterion": "time since prior radiotherapy",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
},
{
"exact_snippets": "At least 4 weeks since prior radiotherapy (unless single fractions for palliation)",
"criterion": "time since prior radiotherapy",
"requirement": {
"requirement_type": "exceptions",
"expected_value": "single fractions for palliation"
}
},
{
"exact_snippets": "Concurrent local palliative radiotherapy for control of bone pain or for other reasons with no curative intent allowed",
"criterion": "concurrent local palliative radiotherapy",
"requirement": {
"requirement_type": "intent",
"expected_value": "no curative intent"
}
},
{
"exact_snippets": "Concurrent whole-brain radiotherapy for brain metastasis allowed",
"criterion": "concurrent whole-brain radiotherapy for brain metastasis",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "No concurrent radiotherapy to sole measurable lesion",
"criterion": "concurrent radiotherapy to sole measurable lesion",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No other concurrent investigational drugs or anticancer therapy",
"criterion": "concurrent investigational drugs or anticancer therapy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "No concurrent preventive IV antibiotics",
"criterion": "concurrent preventive IV antibiotics",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
}
]
}